Nevro Corp., headquartered in Menlo Park, California, develops and commercializes high-frequency spinal cord stimulation (HF-SCS) for the treatment of chronic pain and other disorders. Its flagship product is the Senza HF-SCS system, the only SCS system capable of delivering HF10 therapy up to 10 kHz. The company says its proprietary high-frequency technology appears unique in its potential to treat challenging conditions such as low back pain while enhancing patient experience. The Senza system is authorized for sale and commercially available in Europe and Australia, while in the United States it is limited to investigational use. Nevro has initiated a substantial U.S. pivotal study, built a growing intellectual property portfolio, and demonstrated commercial traction at leading international pain centers. The company plans to complete the pivotal study, seek U.S. regulatory approval, invest in clinical evidence for new indications, and support international and U.S. commercialization. Nevro develops neuromodulation technology for chronic pain relief, including the Nevro Spinal Cord Stimulation System. The company’s Spinal Cord Stimulation System received CE mark in 2010 and is commercially available at leading centers outside the United States. Nevro is privately held and was founded in 2007, headquartered in Menlo Park, California. The company plans to sponsor a pivotal clinical study in the U.S. to support regulatory and clinical development. Management also intends to use new funds to continue its international commercialization strategy and expand into global markets. Current financial activity includes a newly completed $58 million financing to support these development and commercialization efforts.

Total raised

$106M

Funding rounds

2

Latest round

Series C

Latest activity

Mar 2013